Open an account

Liminatus Pharma

LIMN · NASDAQ

$3.22+$0.11 (+3.54%)TodayMarket closed ·
Prev close $3.11

About LIMN

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.

Employees
0
Headquarters
La Palma, California
Listed
May 18, 2021
Sector
Health Care
Industry
Biotechnology
Website
liminatuspharma.com

LIMN key statistics

Market cap
4.33M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
24.70K
Volume
33.07K
Open price
$3.28
High today
$3.30
Low today
$3.05
52 Week high
$141.50
52 Week low
$3.01

Liminatus Pharma (LIMN) at a glance

As of Oct 20, 2026, Liminatus Pharma (LIMN) shares are priced at $3.22, giving the company a market cap of 4.33M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.05 and $3.30. The current price is 5.6% above the day's low and 2.3% below its high.

Volume so far is 33.07K shares, above the average of 24.70K shares a day.

Over the past year Liminatus Pharma has ranged from $3.01 to $141.50, and now sits 0% of the way up that range.

LIMN news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Avi Kapoor

    Dow Gains Over 250 Points; US Jobs Rise By 57,000 In June

  • Mohd Haider

    Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session (UPDATED)

  • Caroline Ryan

    Deal Dispatch: IMAX Mulls Potential Sale, Shein Buys Everlane, West Marine Bankruptcy

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Crude Oil Moves Higher; Walmart Shares Fall After Q1 Results

Similar companies

Companies in the same industry as Liminatus Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.